EA202191063A1 - Новая дозированная форма - Google Patents

Новая дозированная форма

Info

Publication number
EA202191063A1
EA202191063A1 EA202191063A EA202191063A EA202191063A1 EA 202191063 A1 EA202191063 A1 EA 202191063A1 EA 202191063 A EA202191063 A EA 202191063A EA 202191063 A EA202191063 A EA 202191063A EA 202191063 A1 EA202191063 A1 EA 202191063A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dosage form
soft chewable
chewable dosage
dose form
new dose
Prior art date
Application number
EA202191063A
Other languages
English (en)
Inventor
Грегори И. Колл
Джерард П. МАКНАЛЛИ
Вайпул ДЭЙВ
Original Assignee
Джонсон энд Джонсон Консьюмер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джонсон энд Джонсон Консьюмер Инк. filed Critical Джонсон энд Джонсон Консьюмер Инк.
Publication of EA202191063A1 publication Critical patent/EA202191063A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/33—Artificial sweetening agents containing sugars or derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/84—Flavour masking or reducing agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к мягкой жевательной дозированной форме, содержащей первый активный фармацевтический ингредиент, инкапсулированный в липидный материал, который встроен в мягкую жевательную дозированную форму, при этом мягкая жевательная дозированная форма содержит по меньшей мере второй активный фармацевтический ингредиент, а также способ лечения субъекта, страдающего заболеванием или расстройством желудочно-кишечного тракта, с применением мягкой жевательной дозированной формы.
EA202191063A 2018-10-18 2019-10-16 Новая дозированная форма EA202191063A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862747267P 2018-10-18 2018-10-18
PCT/IB2019/058820 WO2020079610A1 (en) 2018-10-18 2019-10-16 Novel dosage form

Publications (1)

Publication Number Publication Date
EA202191063A1 true EA202191063A1 (ru) 2021-07-12

Family

ID=68296592

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191063A EA202191063A1 (ru) 2018-10-18 2019-10-16 Новая дозированная форма

Country Status (6)

Country Link
US (2) US11141375B2 (ru)
EP (1) EP3866770B1 (ru)
CN (1) CN112822998B (ru)
CA (1) CA3112541A1 (ru)
EA (1) EA202191063A1 (ru)
WO (1) WO2020079610A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220331294A1 (en) * 2019-09-27 2022-10-20 Johnson & Johnson Consumer Inc. Gel-chewable dosage form
CN113143876A (zh) * 2020-12-30 2021-07-23 河南合智医药科技有限公司 一种稳定的复方法莫替丁咀嚼片及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597981A (en) 1983-12-20 1986-07-01 Howard Kastin Soft candy composition
US4684534A (en) 1985-02-19 1987-08-04 Dynagram Corporation Of America Quick-liquifying, chewable tablet
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
CA2110313C (en) 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
AU5105398A (en) 1996-11-15 1998-06-03 Fmc Corporation Hydrocolloid delivery system
US6387381B2 (en) 1998-09-24 2002-05-14 Ez-Med Company Semi-moist oral delivery system
CN1662147A (zh) 2002-04-16 2005-08-31 怀泰斯德美国有限公司 功能性成分的传递系统
US7955632B2 (en) 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
EP2028949B1 (en) 2006-04-21 2016-08-17 Intercontinental Great Brands LLC Coating compositions, confectionery and chewing gum compositions and methods
MXPA06010972A (es) 2006-09-25 2009-04-17 World Trade Imp Export Wtie Ag Proceso para estabilizacion de famotidina.
WO2008094877A2 (en) 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US20100092548A1 (en) * 2008-08-28 2010-04-15 Viva Pharmaceuticals Inc. Chewable softgel capsules
US20120107395A1 (en) * 2010-11-01 2012-05-03 Viva Pharmaceutical Inc. Probiotic Soft Gel Compositions
EP2709641B1 (en) 2011-05-16 2017-12-13 Vital Food Processors Limited A dietary supplement
US20130052252A1 (en) 2011-08-25 2013-02-28 Anthony John Bell Hard Coated Confectionary Having A Consumable Soft Chewing Core With A Heat Sensitive Particulate Active And Method For Making Same
WO2013055670A2 (en) 2011-10-11 2013-04-18 Kraft Foods Global Brands Llc Encapsulated sweetener composition, method for the preparation thereof, and chewing gum comprising same
WO2013108686A1 (ja) * 2012-01-17 2013-07-25 ソニー株式会社 情報処理装置および方法、並びにプログラム
US9436672B2 (en) * 2013-12-11 2016-09-06 Power Modes Pty. Ltd. Representing and manipulating hierarchical data
CA2959800A1 (en) 2014-09-05 2016-03-10 Santa Cruz Pharmaceuticals, Inc. Semi-solid chewable dosage form for over-the-counter medications and method for producing same
WO2017091166A1 (en) * 2015-11-26 2017-06-01 Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. Stable pharmaceutical compositions and process for their preparation
WO2017106812A1 (en) 2015-12-19 2017-06-22 First Time Us Generics Llc Soft-chew tablet pharmaceutical formulations
EP3534880B1 (en) * 2016-11-01 2022-05-18 Johnson & Johnson Consumer Inc. Liquid oral pharmaceutical dosage form comprising an histamine h2-receptor antagonist and an antacid

Also Published As

Publication number Publication date
AU2019360443A1 (en) 2021-04-01
WO2020079610A1 (en) 2020-04-23
US20200121594A1 (en) 2020-04-23
EP3866770B1 (en) 2024-10-09
CN112822998B (zh) 2024-09-13
CN112822998A (zh) 2021-05-18
US20210401739A1 (en) 2021-12-30
CA3112541A1 (en) 2020-04-23
EP3866770A1 (en) 2021-08-25
US12083218B2 (en) 2024-09-10
US11141375B2 (en) 2021-10-12

Similar Documents

Publication Publication Date Title
CY1123460T1 (el) Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA202090573A1 (ru) Составы нирапариба
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
EA201792591A1 (ru) Фармацевтические препараты
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
EA202191063A1 (ru) Новая дозированная форма
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX2021006242A (es) Formulaciones de capsula.
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
EA201500044A1 (ru) Лекарственная форма для высвобождения действующих веществ
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
EA201590847A1 (ru) Новые ингибиторы rock
EA201990559A1 (ru) Комбинированная терапия